An update on oral drug delivery via intestinal lymphatic transport

作者：Zichen Zhang, Yi Lü, Jianping Qi, Wei Wu · 发表于：Acta Pharmaceutica Sinica B · 年份：2021 · DOI：10.1016/j.apsb.2020.12.022 · 被引用次数：232 · 研究领域：Advanced Drug Delivery Systems、Gastroesophageal reflux and treatments、Neuroendocrine Tumor Research Advances

Orally administered drug entities have to survive the harsh gastrointestinal environment, penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation. Whereas the gastrointestinal stability can be well maintained by taking proper measures, hepatic metabolism presents as a formidable barrier to drugs suffering from first-pass metabolism. The pharmaceutical academia and industries are seeking alternative pathways for drug transport to circumvent problems associated with the portal pathway. Intestinal lymphatic transport is emerging as a promising pathway to this end. In this review, we intend to provide an updated overview on the rationale, strategies, factors and applications involved in intestinal lymphatic transport. There are mainly two pathways for peroral lymphatic transport-the chylomicron and the microfold cell pathways. The underlying mechanisms are being unraveled gradually and nowadays witness increasing research input and applications.